Steven Mento - Conatus Pharmaceuticals Insider

Conatus Pharmaceuticals Inc -- USA Stock  

USD 5.06  0.05  1%

Co-Founder, CEO and President and Director

Dr. Steven J. Mento, Ph.D., is appointed as President, Chief Executive Officer, Director of Conatus Pharmaceuticals Inc. He is one of cofounders and has served as President and Chief Executive Officer and as a member of board of directors since July 2005. From July 2005 until December 2012, he also served as chairman of the board of directors. He has over 30 years of combined experience in the biotechnology and pharmaceutical industries. From 1997 to 2005, he was President, Chief Executive Officer and a member of the Board of Directors of Idun Pharmaceuticals, Inc. He guided Idun during its transition from a discovery focused organization to a drug development company with multiple products in or near human clinical testing. In April 2005, Idun was sold to Pfizer Inc. Previously, he served as President of Chiron Viagene, Inc., and Vice President of Chiron Corporationrationration from 1995 to 1997. He was Vice President of RD at Viagene from 1992 to 1995. Prior to Viagene, he held various positions at American Cyanamid Company from 1982 to 1992. His last position was Director of Viral Vaccine Research and Development at LederlePraxis Biologicals, a business unit of American Cyanamid. He serves on the boards of directors of BIOCOM, the Biotechnology Industry Organization, BIO Emerging Company Section Governing Body, BIO Health Section Governing Body, Sangamo Biosciences, Inc., and various academic and charitable organizations
Age: 62  CEO Since 2017      
858-376-2600  http://www.conatuspharma.com
Mento holds a B.A. in Microbiology from Rutgers College, and an M.S. and Ph.D. both in Microbiology from Rutgers University.

Management Efficiency

The company has return on total asset (ROA) of (23.97) % which means that it has lost $23.97 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (80.58) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 12.78 M in liabilities with Debt to Equity (D/E) ratio of 37.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Conatus Pharmaceuticals Inc has Current Ratio of 2.71 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Conatus Pharmaceuticals Inc (CNAT) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 25 people. Conatus Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Conatus Pharmaceuticals Inc to your portfolio

Top Management

Conatus Pharmaceuticals Leadership Team
Edward Smith, President, MBA
Michelle Vandertie, Executive
Dan Kisner, Director
James Scopa, Director
Steven Mento, CEO
Daniel Kisner, Director
Preston Klassen, Director
David Hale, Chairman
Harold Wart, Director, Ph.D
William LaRue, Director, MBA
Alfred Spada, Founder, Ph.D
Charles Cashion, President, MBA
Daniel Ripley, President, MBA
Keith Marshall, President, MBA
Louis Lacasse, Director, MBA
Shahzad Malik, Director
David Hagerty, President

Stock Performance

Conatus Pharmaceuticals Performance Indicators